Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Alexander Drilon, Chao Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung Ju Ahn, Matthew G. Krebs, Stephen V. Liu, Thomas John, Gregory A. Otterson, Daniel S.W. Tan, Tejas Patil, Rafal Dziadziuszko, Erminia Massarelli, Takashi Seto, Robert C. Doebele, Bethany Pitcher, Nino Kurtsikidze, Sebastian Heinzmann, Salvatore Siena

研究成果: 雜誌貢獻文章同行評審

1 引文 斯高帕斯(Scopus)

摘要

Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer follow-up, more patients, and the first description of the median overall survival (OS). An exploratory analysis of entrectinib in ROS1 fusion–positive NSCLC with the central nervous system (CNS)–only progression post-crizotinib is reported. Methods: Adults with ROS1 fusion–positive, locally advanced or metastatic NSCLC who received at least one dose of entrectinib and had 12 months or longer of follow-up were included in the analysis. Co-primary end points were confirmed objective response rate (ORR) and duration of response (DoR) by blinded independent central review. The data cutoff was on August 31, 2020. Results: The efficacy-assessable population comprised 168 ROS1 TKI–naïve patients. The median survival follow-up was 29.1 months (interquartile range, 21.8–35.9). The ORR was 68% (95% confidence interval [CI]: 60.2–74.8); the median DoR was 20.5 months. The median progression-free survival (PFS) was 15.7 months and the median OS was 47.8 months. In the 25 patients with measurable baseline CNS metastases, the intracranial ORR was 80% (95% CI: 59.3–93.2), median intracranial DoR was 12.9 months, and median intracranial PFS was 8.8 months. Among 18 patients with CNS-only progression on previous crizotinib treatment, two achieved a partial response (11%) and four had stable disease (22%). In seven patients with measurable CNS disease from this cohort, the intracranial ORR was 14% (1 partial response). Conclusions: Entrectinib is active and achieves prolonged survival in ROS1 TKI–naïve patients with ROS1 fusion–positive NSCLC. Modest activity is seen in patients with CNS-only progression post-crizotinib.
原文英語
文章編號100332
期刊JTO Clinical and Research Reports
3
發行號6
DOIs
出版狀態已發佈 - 6月 2022
對外發佈

ASJC Scopus subject areas

  • 腫瘤科
  • 肺和呼吸系統醫學

指紋

深入研究「Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC」主題。共同形成了獨特的指紋。

引用此